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treatments. METHODS: The model is based on pub-
lished treatment guidelines for LBP, modified to reflect
usual care. The model focuses on three types of patients,
those who (1) self-treat only, (2) visit their primary care
physician, and (3) visit a physical therapist. To establish
baseline costs, we included published estimates of health-
care resource utilization, including medications, visits to
healthcare professionals, and various procedures and mo-
dalities. We also included published and calculated esti-
mates of time lost from work due to LBP and provider
visits. The economic analysis takes three perspectives: pa-
tient, healthcare provider, and employer. RESULTS: At
baseline, the employer bears the largest portion LBP costs
($583 per episode), followed by the managed care orga-
nization ($197), and the patient ($56). In exploratory
analyses of a wearable heat wrap that improves physical
functioning during an LBP episode, and shortens the epi-
sode’s length, all stakeholders saved money regardless of
the intervention cost, and experienced the non-monetary
benefits of successfully treating LBP. The employer achieved
the greatest savings. CONCLUSIONS: LBP is a costly
health problem. When evaluating treatments for LBP, it
is important to measure the intervention’s effects on ab-
senteeism and healthcare resource utilization, as well as
pain and physical functioning.
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Acute muscular low back pain (LBP) accounts for over
$30 billion in US annual medical costs, and is the second
leading cause of absenteeism. It represents 16% of work-
ers’ compensation claims and 33% of workers’ compen-
sation costs. LBP is treated by a variety of healthcare
providers (e.g., primary care physicians, physical thera-
pists, chiropractors, and patients). Each of these provid-
ers has a unique treatment approach, which is under-
standable, because it is unlikely that any one treatment
would be beneficial if applied indiscriminately to all LBP
patients. Thus, it would be difficult to develop universal
LBP treatment guidelines. OBJECTIVE: In an effort to
develop an economic model of LBP treatments, we evalu-
ated whether usual practice deviates substantially from
treatment guidelines. METHODS: We compared treat-
ment guidelines compiled by the Agency for Health Care
Policy and Research, and the American Academy of
Orthopaedic Surgeons and the North American Spine
Society to published LBP practice patterns. We also inter-
viewed nationally recognized LBP researchers and cli-
nicians. RESULTS: We found that the treatment guide-
lines are more conservative than usual care. Most
healthcare resources reported in the literature by LBP suf-
ferers and healthcare providers were not specifically rec-
ommended by the guidelines. In addition, the guidelines
and clinical practice suggest treatment practices that do
not require a physician’s supervision. The reliance on
“self-treatment” indicates that patient education initia-
tives may be more fruitful social investments. CONCLU-
SIONS: A variety of healthcare providers treat LBP,
and their approaches vary substantially. No single pro-
vider’s approach seems directly derived from treatment
guidelines. Because of widespread “self-treatment” of
LBP, patient education could yield significant healthcare
savings.
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BACKGROUND: The availability of atypical antipsy-
chotics varies substantially in the UK. Several drug proto-
cols are available for treatment of people with first epi-
sode schizophrenia. Current evidence doesn’t compare
the relative efficiency of these protocols for first episode
schizophrenia. OBJECTIVES: To compare the relative
costs and quality adjusted life years (QALYs) at three
years of 8 antipsychotic protocols for first episode schizo-
phrenia. METHODS: Data were estimated from system-
atic reviews, UK specific statistics and published literature.
A decision analytic model was used with Monte-Carlo
simulation analysis to estimate the expected costs and
QALYs (95% confidence intervals). RESULTS: The 8
protocols gave 32 combinations of drug sequences. The
mean (95% CI) expected costs and QALYs per person for
1st line therapy were: chlorpromazine, £19,600–£21,100
(£19,400–£21,300) and 2.20–2.35 (2.19–2.35); haloperi-
dol £22,800–£24,300 (£22,600–£24,600) and 2.18–2.27
(2.17–2.27); risperidone, £22,911–£22,961 (£22,700–
£23,200) and 2.35 (2.34–2.36); olanzapine £26,800–
£26,994 (£26,500–£27,300) and 2.28–2.31 (2.28–2.31).
The incremental cost/QALY of risperidone versus chlor-
promazine was £54,755–£663,170. The ranking of ex-
pected costs and QALYs were similar for 2nd, 3rd and 4th
line therapy. The incremental cost/QALY of risperidone
versus chlorpromazine was £14,300–£26,000. The incre-
mental cost/QALY of clozapine versus chlorpromazine
for 3rd and 4th line only was £13,700–£18,000. CON-
CLUSIONS: Chlorpromazine may be more efficient as 1st
line therapy. Risperidone and clozapine may be more ef-
ficient for patients failing 1st and subsequent therapy.
The results are uncertain: (i) the analyses were explor-
atory; (ii) differences in expected costs and QALYs may
not be economically important (iii) the quality of clinical
and utility data was poor; (iv) some side effects were ex-
cluded due to lack of data.
